SynthesisMedicine2018
The clinical effects of probiotics for inflammatory bowel disease: A meta-analysis.
Synthesis in Medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 39 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 65 citations in OpenAlex.
- Preclinical evidence of probiotics in ulcerative colitis: a systematic review and network meta-analysis.Frontiers in pharmacology · 2023Pooled it
- Probiotics as a Coadjuvant Factor in Active or Quiescent Inflammatory Bowel Disease of Adults-A Meta-Analytical Study.Nutrients · 2020Pooled it
- Modulation of Innate Immunity by Short-Chain Fatty Acids in Probiotic and Fecal Microbiota Transplantation Therapies for the Treatment of Colon Disorders.Probiotics and antimicrobial proteins · 2026Review
- AI-Guided Multi-Omic Microbiome Modulation Improves Clinical and Inflammatory Outcomes in Refractory IBD: A Real-World Study.International journal of molecular sciences · 2025Article
- The Hygienic Significance of Microbiota and Probiotics for Human Wellbeing.Probiotics and antimicrobial proteins · 2025Review
- Probiotics and inflammatory bowel disease: an umbrella meta-analysis of relapse, recurrence, and remission outcomes.Nutrition & metabolism · 2025Review
- Microbial remodeling of gut tryptophan metabolism and indole-3-lactate production regulate epithelial barrier repair and viral suppression in human and simian immunodeficiency virus infections.Mucosal immunology · 2025Article
- Living Engineered Bacterial Therapeutics: Emerging Affordable Precision Interventions.Microbial biotechnology · 2024Review
- Extracellular Vesicles of the ProbioticNutrients · 2024Article
- Modulation of Serotonin-Related Genes by Extracellular Vesicles of the ProbioticInternational journal of molecular sciences · 2024Article
- The Potential Impact of Probiotics on Human Health: An Update on Their Health-Promoting Properties.Microorganisms · 2024Review
- Saccharomyces boulardii enhances anti-inflammatory effectors and AhR activation via metabolic interactions in probiotic communities.The ISME journal · 2024Article
- Role of prebiotics, probiotics, and synbiotics in management of inflammatory bowel disease: Current perspectives.World journal of gastroenterology · 2023Review
- Intestinal Microbiota and miRNA in IBD: A Narrative Review about Discoveries and Perspectives for the Future.International journal of molecular sciences · 2023Review
- A review of the auditory-gut-brain axis.Frontiers in neuroscience · 2023Review
- Host microbiome in tuberculosis: disease, treatment, and immunity perspectives.Frontiers in microbiology · 2023Review
- Emerging strategies for engineering Escherichia coli Nissle 1917-based therapeutics.Trends in pharmacological sciences · 2022Review
- Empiric Antibiotics in COVID 19: A Narrative Review.Cureus · 2022Review
- Therapy Strategies for Children Suffering from Inflammatory Bowel Disease (IBD)-A Narrative Review.Children (Basel, Switzerland) · 2022Review
- Lactobacillus spp. for Gastrointestinal Health: Current and Future Perspectives.Frontiers in immunology · 2022Review
Corrections and comments
- Erratum issued
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAs the exact pathogenesis of inflammatory bowel disease (IBD) is not known, there is increasing evidence of clinical trials and animal models that indicate the beneficial effects of probiotics.
methodsMultiple databases were adopted to search for the relevant studies involving the comparison between probiotics and control groups. Review Manager 5.0 was used to assess the efficacy among included articles. Risk of bias for the articles included was also conducted.
resultsFinally, 10 studies eventually met the inclusion criteria and 1049 patients were included. The meta-analyses showed that no significant differences of remission, relapse, and complication rate between Escherichia coli Nissle 1917 and mesalazine groups (RR = 0.94, 95%CI [0.86, 1.03], P = .21; RR = 1.04, 95%CI [0.82, 1.31], P = .77; RR = 1.12, 95%CI [0.86, 1.47], P = .39, respectively). Despite the fact that no significant differences of remission, relapse, and complication rate were observed in overall meta-analysis results between probiotics and placebo group, the subgroup analyses suggested that VSL#3 presented a higher remission rate and lower relapse rate (RR = 1.67, 95%CI [1.06, 2.63], P = .03; RR = 0.29, 95%CI [0.10, 0.83], P = .02, respectively).
conclusionSome types of probiotics, such as E coli Nissle 1917 and VSL#3, could be used as alternative therapy for patients with IBD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.